MYRIAD GENETICS INC (MYGN) — insider trading
Health Care · NASDAQ
MYRIAD GENETICS INC (MYGN) has 20 reported SEC Form 4 insider transactions in our data, including 1 open-market purchase and 1 open-market sale among the most recent 20 (latest 2026-09-21).
Recent Form 4 transactions
| Date | Insider | Role | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| 2026-09-21 | Wheeler Benjamin Richard | Officer (Chief Financial Officer) | Shares withheld for taxes / exercise cost | 2,555 | $4.01 | $10.2K | Form 4 |
| 2026-09-16 | Sikri Vishal | Officer (EVP, Commercial) | Grant / award / vesting | 257,731 | — | $0 | Form 4 |
| 2026-09-03 | Fox Jennifer Lynne | Officer (Chief Legal Officer) | Shares withheld for taxes / exercise cost | 4,398 | $3.23 | $14.2K | Form 4 |
| 2026-08-16 | Wheeler Benjamin Richard | Officer (Chief Financial Officer) | Shares withheld for taxes / exercise cost | 8,761 | $3.03 | $26.5K | Form 4 |
| 2026-06-11 | Donnelly Brian J | Officer (Chief Commerical Officer) | Grant / award / vesting | 5,000 | $3.94 | $19.7K | Form 4 |
| 2026-06-11 | Raha Samraat S. | Director, Officer (President and CEO) | Grant / award / vesting | 3,542 | $3.94 | $13.9K | Form 4 |
| 2026-06-08 | Kumar Rashmi | Director | Open-market sale | 15,000 | $4.46 | $66.8K | Form 4 |
| 2026-06-04 | Kumar Rashmi | Director | Grant / award / vesting | 59,701 | — | $0 | Form 4 |
| 2026-06-04 | Bisaro Paul | Director | Grant / award / vesting | 59,701 | — | $0 | Form 4 |
| 2026-06-04 | Reitan Colleen F | Director | Grant / award / vesting | 59,701 | — | $0 | Form 4 |
| 2026-06-04 | Dreismann Heinrich | Director | Grant / award / vesting | 59,701 | — | $0 | Form 4 |
| 2026-06-04 | Phanstiel S. Louise | Director | Grant / award / vesting | 59,701 | — | $0 | Form 4 |
| 2026-06-04 | Davis Mark Steven | Director | Grant / award / vesting | 59,701 | — | $0 | Form 4 |
| 2026-06-04 | Newcomer Lee Nisley | Director | Grant / award / vesting | 59,701 | — | $0 | Form 4 |
| 2026-06-04 | Skovronsky Daniel | Director | Grant / award / vesting | 59,701 | — | $0 | Form 4 |
| 2026-06-01 | Jampa Raj | Officer (Chief Technology Officer) | Grant / award / vesting | 251,889 | — | $0 | Form 4 |
| 2026-05-14 | Bisaro Paul | Director | Open-market purchase | 7,500 | $3.69 | $27.6K | Form 4 |
| 2026-05-01 | Donnelly Brian J | Officer (Chief Commerical Officer) | Shares withheld for taxes / exercise cost | 55,975 | $4.80 | $268.7K | Form 4 |
| 2026-04-14 | Muzzey Dale | Officer (Chief Scientific Officer) | Shares withheld for taxes / exercise cost | 946 | $4.91 | $4.6K | Form 4 |
| 2026-04-14 | Verratti Mark | Officer (Chief Operating Officer) | Shares withheld for taxes / exercise cost | 1,069 | $4.91 | $5.2K | Form 4 |
Ask the chat about MYGN's insider activity →
Transaction types are the SEC Form 4 codes: open-market purchases (P) and sales (S) are the only rows that reflect open-market conviction. Awards/vesting (A), option exercises (M/X/C), shares withheld for taxes (F) and gifts (G) are compensation or mechanical, not buying or selling on the open market. Sales may be planned and non-discretionary (e.g. a Rule 10b5-1 plan); open-market buying is not a recommendation to buy. Informational only — not financial advice.
Source: SEC EDGAR Form 3/4/5. See the full company profile: MYRIAD GENETICS INC (MYGN).
Last updated 2026-09-21 (most recent filing date).
Informational only — NOT financial advice. Insider filings are sourced from SEC EDGAR and shown with their reported dates.